Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #195259 on Anavex Life Sciences Corp (AVXL)
nidan7500
06/03/19 9:24 AM
#195260 RE: nidan7500 #195259
The ANAVEX 2-73 study incorporates an adaptive design, with an enrollment of 32 mild to moderate Alzheimer's disease patients. Key performance measures will be collected over 6 months, at up to seven (7) sites in Australia. COGNISION™ is an easy to use, reliable system that provides physiological measures of cognitive processing ("cognitive biomarkers"). These biomarkers are particularly important in pharmaceutical development of pro-cognitive therapeutics by providing sensitive measures of targeted drug effects.